NCT00154297

Efficacy and Safety of Early Versus Delayed Administration of Everolimus in de Novo Renal Transplant Patients

A National Multicentre Randomized Study Comparing the Early Versus Delayed Administration of Everolimus in de Novo Kidney Transplant Recipients at Risk of Delayed Graft Function

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 139 (actual)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate if the delayed administration of everolimus could reduce the everolimus associated "anti-proliferative complications" (e.g. wound healing disorder) while maintaining efficacy, when compared to the immediate administration of everolimus in de novo renal transplant patients.

Conditions

• Renal Transplantation

Interventions

Type	Name	Description
DRUG	Everolimus (RAD001)

Timeline

• Start date: 2005-06-01
• Primary completion: 2008-06-01
• First posted: 2005-09-12
• Last updated: 2011-04-04
• Results posted: 2011-01-26

Locations

1 site across 1 country: Switzerland